Suppliers · Research / RTO · Discovered — similar established company
ACD Pharma
Growing resistance against antibiotics is quickly becoming the greatest threat to human health. The use of antibiotics in food production is partly to blame. With that backdrop, it was a small sensation when ACD Pharma in 2018 got the approval for a phage product that efficiently removes a harmful bacteria and outbreaks of a disease which has antibiotics as its only cure. Bacteriophages, or …
Profile
- Industry
- Crop protection, Fishery & aquaculture, Post-harvest & processing, Seeds & genetics, Veterinary
- Topics
- Shrimp/fish genetics & aquaculture tech, Biopesticides & biocontrol, Livestock & poultry production/genetics
- Role
- Research / RTO — “…: linked with the Norwegian University of Life Sciences and their own bacteriophage laboratory in Lofoten. - F…”
- Why it is bioeconomy
- ACD Pharma is a Norwegian company that develops and manufactures bacteriophage-based biocontrol products for the aquaculture industry and is researching applications for human and veterinary medicine to combat antibiotic resistance.
- Found via
- [Rubric] Austria · phages; [Rubric] Denmark · phages; [Rubric] Finland · phages; [Rubric] Iceland · phages
Bio-solutions it supplies 0
Not yet cited as a supplier in a graded solution.
What they offer
This company does not publish its products or services — we find out through an introduction.
News & status 6
- 2025-02-11 Tydelig fotavtrykk på Norway Life Science 2025 – LegemiddelindustrienACD Pharma presented as a pioneer in phage-based solutions, highlighting Custus—the world’s first bacteriophage product used in Norwegian salmon farming to combat Yersinia ruckeri—and noting that phage therapies for humans are mainly challenged by cost, not …
- 2025-08-20 Fiskehelseselskapene markerte seg på Aqua Nor – LegemiddelindustrienACD Pharma had a presence at Aqua Nor alongside other LMIs members, likely hosting or participating in stands or activities over the three-day event.
- 2026-07-02 We're proud to announce that ACD has entered into a venture philanthropy agreement with Ultragenyx, committing $4 million to advance the clinical development of an investigational therapy for Creatine Transporter Deficiency (CTD).ACD Pharma (ACD) has forged a venture philanthropy agreement with Ultragenyx, committing $4 million to advance a CTD investigational therapy, marking the largest research investment in ACD’s history and a milestone for their Race for a Cure initiative.
- 2025-02-03 Terclara (MOB-015) is now being launched in NorwayMoberg Pharma and Allderma announce Terclara (MOB-015) is being launched in Norway, following success in Sweden. The rollout relies on a new terbinafine supplier and begins with pharmacy deliveries in February, supported by targeted education and consumer …
- 2025-08-26 Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary FibrosisCalluna Pharma (not ACD Pharma) announces progression of CAL101 for IPF, including initiation of Phase 2 AURORA with 150 patients across 50+ sites, and later announces full enrollment completed ahead of plan and FDA Orphan Drug designation for CAL101. If you …
- 2025-10-24 Pharmaceutical volumes and rates weaken this year as pressure grows - The LoadstarACD Pharma remains a strong, above-2019 level market, but its rate premiums are weakening relative to general cargo due to supply-side capacity and investments in pharma. The market is increasingly concentrated among large forwarders (with ~70% share) while a …
Network: owners, partners, peers
Ownership & investors 1
| parent | independent |
Similar companies
Phagos · Phageguard · Micreos · Proteon Pharmaceuticals · PHAXIAM Therapeutics · NexaBiome · Pherecydes Pharma · Inteliphage
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member